EQRx Aims To Dent Saturated, But Still Expensive, PD-1 Market

Partner CStone Announces Positive NSCLC Results For Sugemalimab

 
• By Alaric DeArment
Price drop
EQRx is aiming for the PD-1 inhibitor market with a cheaper contender from a Chinese company • Source: Shutterstock

More from Immuno-oncology

More from Anticancer